-
ESMO BC 2024 | Professor Yiding Chen: Updated CAPItello-291 Study Data Pioneers Precision Therapy for the PAM Pathway in the Post-CDK4/6i Era
On May 16, 2024, the European Society for Medical Oncology Breast Cancer Annual Meeting (ESMO BC) reported updated results from the CAPItello-291 study (183MO). The data showed that the AKT inhibitor capivasertib combined with fulvestrant provided benefits in second-line treatment without affecting the benefits of subsequent treatments. This further solidified capivasertib’s role in the post-CDK4/6…
-
ASCO 2024 | Professor Yu Chen: First-In-Class PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 for Advanced Melanoma
The highly anticipated 2024 American Society of Clinical Oncology (ASCO) Annual Meeting has officially begun. As a premier global academic conference in oncology, ASCO attracts professionals from around the world to share and discuss the latest clinical oncology research findings and treatment advancements. At this year’s conference, the research led by Professor Yu Chen from…
-
EHA China Voice丨Professor XiaoyanKe and Professor Kai Hu’sTeam: Bridging Radiotherapy Before CAR-T Treatment Improves Survival in Refractory/Relapsed, Multidrug-Resistant CNS B-Cell Lymphoma Patients
As the efficacy of CAR-T therapy in B-cell lymphoma becomes increasingly recognized, some studies have focused on its application in treating refractory/relapsed central nervous system (CNS) B-cell lymphoma. Refractory/relapsed CNS B-cell lymphoma patients were initially excluded from early CAR-T clinical trials, but as CAR-T therapy’s real-world application grows, these patients can achieve optimistic outcomes. However,…
-
Haematologica丨ANCHOR Study: Dose Exploration of Melflufen Combined with Multi-Drug Therapy in Relapsed/Refractory Multiple Myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy and is a disease of terminally differentiated plasma cells. As MM progresses, treatment becomes increasingly difficult, and the periods of remission after each relapse grow shorter. There is an urgent need for new therapeutic combinations that can provide deeper and more durable responses. Recently, Haematologica…
-
Venetoclax±BTKi-Based Chemotherapy as a Potential Bridging Therapy Before CAR-T Treatment for Relapsed/Refractory B-Cell Lymphoma
The efficacy of CAR-T therapy in B-cell lymphoma is increasingly recognized, and its real-world application is expanding. However, patients with high tumor burden face a high incidence of cytokine release syndrome (CRS) and poor outcomes, leading to high treatment-related mortality. There is an urgent need for effective bridging therapies to reduce CRS incidence and improve…
-
Lancet Haematol丨HOPE-B Trial: Long-Term Follow-Up Results of Gene Therapy for Hemophilia B
Hemophilia B is characterized by a deficiency in clotting factor IX due to mutations in the F9 gene, impairing coagulation and increasing bleeding risk. Predominantly affecting males, hemophilia B can be classified as mild (factor IX activity >5% and
-
JCO丨EURO-SKI Study: Final Analysis and New Prognostic Factors for Treatment-Free Remission in CML
For chronic myeloid leukemia (CML) patients who achieve deep and durable molecular remission, the feasibility of discontinuing tyrosine kinase inhibitors (TKIs) has been established, challenging the notion of lifelong dependency on TKIs. Achieving treatment-free remission (TFR) without affecting overall survival (OS) is a key objective in current CML treatment. Recently, the Journal of Clinical Oncology…
-
ASCO China Voice | Two Studies by Professor Jiayu Wang from Academician Binghe Xu’s Team Selected for ASCO
The 2024 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be held from May 31 to June 4 in Chicago, Eastern Time. Two studies led by Professor Jiayu Wang from Academician Binghe Xu’s team at the Cancer Hospital of the Chinese Academy of Medical Sciences (CAMS) have been selected for poster presentation…
Connecting Medical Expertise through Media